OBJECTIVE. The neonatal abstinence scoring system proposed by Finnegan is used widely in neonatal units to initiate and to guide therapy in babies of opiate dependent mothers. The purpose of this study was to assess the variability of the scores in newborns and infants not exposed to opiates during the first three days of life and during 3 consecutive days in week 5 or 6. PATIENTS AND METHODS. Healthy neonates born after 34 completed weeks of gestation whose parents denied opiate consumption and gave informed consent were included in this observational study. Infants with signs or symptoms of disease or with feeding problems were excluded. A modified scoring system was used every 8 hours during 72 hours by trained nurses. 102 neonates were observed for the first 3 days of life and 26 neonates in week 5 to 6. A meconium sample and a urine sample at week 5 to 6 were stored from all infants to be analysed for drugs when the baby scored high. Given a non-Gaussian distribution the scores were represented as percentiles.
Introduction
Withdrawal symptoms in an infant born to a mother addicted to heroin were first described 50 years ago. 1 In 1975 Loretta Finnegan published a scoring system for the neonatal abstinence syndrome she had devised as both a clinical and investigative tool. 2 This score lists all relevant clinical signs of withdrawal in newborn infants during the first days of life comprehensively, and assesses central nervous system hyperirritability, gastrointestinal dysfunction, respiratory distress and vague autonomic signs in a semi-quantitative way. Unfortunately these signs lack specificity.
Originally Finnegan suggested that the score should be further improved in order to avoid "ambiguous and redundant items which may contribute to the error variance" 2 .
As a consequence a variety of modified Finnegan scores, as they were called, have been widely used to guide and compare various therapies of the neonatal abstinence syndrome. 3 As substance abuse during pregnancy is still a common problem in many countries, the Finnegan score is still useful today. 4 Compared with the original version, the following modifications of the Finnegan score are usually applied: 5 "Hyperactive Moro reaction" was dropped since it is a sign of central nervous system hyperirritability and therefore redundant to "tremors". "Moyoclonic jerks" shown to be highly specific for opiate withdrawal were added instead. 6 Excoriations on nose, knees or toes were changed to "excoriation of the skin" and only one point was given instead of one for each area. Excoriations of the skin are due to vigorous movements and thus also consequences of central nervous system hyperirritability. Since newborns are, in contrast to the 1970s, put to sleep on their back, these excoriations are no longer seen on nose or knees.
In clinical practice scores above 8 are considered high and suggestive of neonatal withdrawal. Pharmacological treatment of withdrawal is started if the modified Finnegan score is above 9 on at least two occasions. Originally the scoring was applied every 4 hours, which may be appropriate for scientific purposes. For clinical use scoring every 8 hours, i.e. once per shift, proved to be adequate.
Although the score is widely used there are only few studies that assess its reliability and validity. We therefore applied the score to a cohort of non-addicted neonates and infants to define its variability in the absence of drug withdrawal, its day-night cycles and its course with age.
Methods 102 healthy neonates born after 34 completed weeks of gestation whose parents denied opiate consumption and gave informed consent were included in this observational study. Exclusion criteria were malformations, birth trauma, and infants at increased risk for group B streptococcus infection (mother carrier without appropriate antibiotic prophylaxis).
Each infant was examined and history about alcohol, nicotine or drug use during pregnancy was taken from the mother. A meconium sample was collected and stored in a deep freezer. These samples were later analysed for substances in all cases in whom Finnegan score exceeded the 95 th percentile once or the 90 th percentile twice during the observation period to exclude drug exposure during pregnancy. Meconium analysis offers an accurate method of quantifying the level of drug misuse in pregnancy as shown in several large studies. [7] [8] [9] The meconium samples were analysed by a validated procedure which consisted of the extraction of the drugs abused by the mother into organic solvents and thereafter an immunological drug screening test (Roche, Basel, Switzerland). Positive results were confirmed with high pressure liquid chromatography (HPLC) (Remedi, BioRad, Riehen, Switzerland).
The infants were observed in the maternity ward by trained nurses. Episodes of sleeping, crying and feeding were noted for the first 72 hours. A modified Finnegan score ranging from 0 to 37 was applied every 8 hours (Table 1) . 26 infants of the original cohort were observed again at week 5 or 6 of life for 72 consecutive hours. Infants who had feeding problems, had been vaccinated during the last two days, showed any signs or symptoms of disease or whose parents were unlikely to comply were excluded. The same nurses who had observed the infants during the first three days assessed the infants at home at 8 am, at 4 pm and at midnight for three consecutive days assisted by the mothers who had been instructed to monitor their infants during their first three days at hospital. The same observation form with 8 hour assessments of the modified Finnegan score was used as for the first 3 days. A urine sample was deep frozen for investigation of drugs if scores were once above the 95 th percentile or twice above the 90 th percentile. Urine samples were analysed using commercial automated drugs-of-abuse immunoassays on the Integra instrument (Roche, Basel, Switzerland).
The study protocol was approved by the local ethics committee and all parents gave informed consent.
The results were plotted with percentiles given a non-Gaussian distribution of the scores. The upper limit of the normal range was defined at the 95th percentile. Mann Whitney U test was used to compare two groups with significance level at 0.05.
Results
The characteristics of the infants included in cohort 1 (first 72 hours) and cohort 2 (week 5 or 6) are given in table 2. The two cohorts did not differ significantly in any aspect. 15 (4) mothers reported smoking 1 to 10 cigarettes per day and 5 (1) mother reported sporadic alcohol intake never exceeding 2 glasses of wine during pregnancy.
All mothers denied illicit drug consumption.
In cohort 1 median scores remained stable during the first three days of life at 2, but the variability increased, P95 raising from 5.5 on day 1 to 7 on day 2 (figure 1). Five infants had scores between 8 and 11 at one assessment but dropped below 8 at the next assessment. Meconium analysis done in these infants did not reveal opiates, methadone, cocaine, benzodiazepines, barbiturates or amphetamines.
There was no statistically significant difference between girls and boys and between day and night. Infants delivered by Ventouse or whose mothers had smoked during pregnancy did not show higher scores than the others. A detailed analysis of the singular components showed that high pitched cry, short sleep after feeding, vomiting and sneezing were frequent during the whole observation period (figure 2).
At week 5 to 6 median values were significantly higher during day time (50th percentile=5, 95th percentile=8) than during night time (50th percentile=2, 95th percentile=6; p=0.02) (figure 3). Sleep duration after feeding and sneezing contributed most to the circadian cycles ( figure 4 ). Urine samples of six infants with high scores were analysed for opiates, methadone, amphetamines, cocaine, barbiturates and benzodiazepines. None of those substances were detected.
Discussion
We report the distribution of the Finnegan score in infants not exposed to drugs in utero. These findings are important for the interpretation of the score in neonatal 6 abstinence syndrome, giving a baseline for healthy infants against which withdrawal symptoms can be compared. As the 95th percentile never exceeds 8, this cut-off may be reasonable to raise suspicion for drug withdrawal and to initiate pharmacological treatment in infants of substance abusing mothers.
We were not able to find a similar study with an extended literature search in MEDLINE and EMBASE. Two important features of the score have to be pointed out:
1) The score increases with age. This phenomenon is related to brain maturation and reflects well known developmental changes in behaviour, especially in crying patterns. 10 2) A circadian rhythm is established by week 5 or 6. This fact also reflects developmental maturation. 11 It is noteworthy that this variation is mainly due to longer duration of night sleep.
The original score suggested by Finnegan was modified, as described in the introduction. As the modified items occurred very rarely in our cohort, the results are hardly affected by these modifications.
The strengths of this study are the selection of patients with exclusion of drug ingestion by meconium analysis in subjects with high scores, the inclusion of patients after Ventouse delivery and nicotine exposure before birth, the use of an observation scheme identical to that used in narcotic abstinence syndrome by nurses who have experience with scoring infants with withdrawal symptoms.
The weaknesses are that the score was applied by various nurses and in part by the parents for week 5 or 6, which may increase variability. A video recording which would allow post-hoc analysis would be more objective but need much more time without improving variability.
Up to 5% of infants born to mothers not reporting drug use may have been exposed to opiates in utero. 8, 12 We examined meconium or urine samples only in infants with high scores in order to ensure that these elevated scores were not due to an unknown opiate abstinence syndrome. Our methodology does not exclude that an infant with permanent low scores was exposed to opiates in utero. This limitation does not affect our results, at least not the 95 th percentile, because any infant with significant signs of opiate withdrawal should have been detected.
Monitoring the abuse of drugs during pregnancy is a difficult task, as mothers may take these drugs intermittently and urine tests therefore may be negative. Instead, 7 the analysis of meconium samples, which act as garbage accumulation bin during the last 5 months of pregnancy, is the contemporary approach for detecting drug exposure in neonates. As no standardised procedure for the extraction and analysis of meconium samples has been published to date, each laboratory has to develop and validate its own procedure. This leads to different results of meconium drug screening tests in different laboratories. Therefore, clinical methods are indispensable for the identification of infants suspected to narcotic withdrawal. 13
Conclusions
From this study there are two implications for the use of the Finnegan score: In infants who score higher than 8, narcotic withdrawal should be suspected. If the score is used to guide therapy for abstinence syndrome, an increase of the baseline and day-night-cycles present at 5 to 6 weeks have to be taken into account. 
